Articles

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA
Division of Chemical Therapeutics, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA
Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA
Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, USA
Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, USA
Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA
Vol. 97 No. 11 (2012): November, 2012 https://doi.org/10.3324/haematol.2012.062539